Abstract
The implementation of a program on routine antenatal anti-D prophylaxis (RAADP) in the developed world has led to a significant decline in the residual numbers of Rhesus negative women becoming sensitized. However, a significant number of Rhesus D negative women in SSA are not fortunate because of lack of access to prophylactic immunoglobulin D and thus they continue to be affected. The management of Rhesus negative pregnancy in Sub-Saharan Africa is associated with several daunting challenges: absence of a policy on universal access to Rh D immunoglobulin, lack of fetomaternal testing facilities, unaffordability of prophylactic anti-D immunoglobulin, poor uptake of quality antenatal care, poor health infrastructure, sub optimal management of potentially sensitizing events during pregnancy, shortage of qualified medical personnel, poor data management, high incidence of illegal abortion and quackery. There is a need for the formulation of necessary guidelines on Rhesus immunoprophylaxis in SSA. Health authorities need to implement evidence-based policy on universal access to anti-D immunoglobulin. There is also the need to optimize the knowledge of obstetricians on anti-D prophylaxis, implementation of the readily available and affordable Kleihauer fetomaternal haemorrhage testing for all women who experience a potentially sensitizing event antenatally post 20 weeks gestation and postnatally. These factors can facilitate the effective management of Rh negative pregnancy in the region and reduce the risk of Rhesus D immunization and Rhesus D haemolytic disease of the foetus and newborn.
Highlights
The term pregnancy refers to an ovum fertilized by spermatozoa implanting itself to the maternal uterus with subsequent development of an embryo and growth into a foetus over a mean period of 9 months
It is the best practice to carry out Feto Maternal Haemorrhage (FMH) testing on all Rh-negative women who undergo termination of pregnancy, miscarriage and those delivered of a Rh-Positive baby within 72 hours, to determine the volume of foetal red cells that may have entered the maternal circulation in such sensitizing events, to enable the administration of optimum amount of antiD immunoglobulin to prevent the mother from being sensitized, and to prevent haemolytic disease of the foetus and newborn (HDFN) in subsequent Rh-positive pregnancies
First trimester indications of 50 microg immunoglobulin D is recommended in cases of ectopic pregnancy
Summary
The term pregnancy refers to an ovum fertilized by spermatozoa implanting itself to the maternal uterus with subsequent development of an embryo and growth into a foetus over a mean period of 9 months. It is the best practice to carry out Feto Maternal Haemorrhage (FMH) testing on all Rh-negative women who undergo termination of pregnancy, miscarriage and those delivered of a Rh-Positive baby within 72 hours, to determine the volume of foetal red cells that may have entered the maternal circulation in such sensitizing events, to enable the administration of optimum amount of antiD immunoglobulin to prevent the mother from being sensitized, and to prevent HDFN in subsequent Rh-positive pregnancies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.